• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

The Global Orthobiologics Market - Players, Products and Technologies Driving Change 2008

Posted on: Wednesday, 21 May 2008, 12:00 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c92536) has announced the addition of "The Global Orthobiologics Market - Players, products and technologies driving change 2008" to their offering.

The primary advantage of synthetic bone graft substitutes and growth factors compared with allograft bone tissue is that they do not depend on the availability of donated human tissue. In addition, owing to the potential risk of disease transmission, synthetic materials and growth factors may be perceived as safer than allograft-based bone tissue. Many new composite products are also becoming available which seek to harness the combined characteristics of synthetic and natural materials in one single product optimised for rapid bone repair and regeneration.

Stem cell therapy is also showing huge potential as an alternative to autograft. Mesenchymal stem cells (MSCs) found in bone marrow, can form a variety of cells in the laboratory, including fat cells, cartilage, bone, tendon and ligaments, muscles cells, skin cells and even nerve cells. Unlike most other human adult stem cells, MSCs can be obtained in quantities appropriate for clinical applications, making them good candidates for use in tissue repair. They also offer the advantage of low morbidity and cost.

The last twelve months has seen consolidation in the orthobiologic sector, although most of the acquisitions have been relatively small in terms of money. The largest acquisition, and of particular interest, is the rather surprising entry into the segment of negative-pressure woundcare company, Kinetic Concepts, with its proposed acquisition of LifeCell, a leading provider of biological products for soft tissue repair, for US$1.7 billion.

The emergence of gene therapy?

Gene therapy has the potential to provide the ideal solution for treating a variety of musculoskeletal disorders. The promise of gene therapy is the ability to efficiently transfer new genetic material into patient cells to either replace defective genes or introduce therapeutic genes in order to treat disease.

To date, much of the research in gene therapy for the enhancement of spine fusion has centred on the transfer of genes-encoding BMPs and related proteins. Recombinant, osteogenic growth factors are now available to enhance bone repair, particularly in those applications related to the treatment of fracture non-unions and the enhancement of fusion of the spine. However, there is concern that a single dose of an exogenous protein will not induce an adequate osteogenic signal in many patients, particularly in those cases where there is a compromise of host bone and the surrounding soft tissue.

Questions answered

What will the value of stem cell therapies be in 2012?

What are the market growth drivers for the allograft tissue market?

What are the advantages and disadvantages of platelet-derived growth factors?

The synthetic bone graft market was estimated to be worth US$250 million in 2007. By what annual rate is it expected to grow over the next 5 years?

Who are the companies with novel technology in the soft tissue repair area?

What is DePuy's product line-up in the orthobiologics sector?

What is Genzyme's interest in China?

With which Australian company did Smith & Nephew sign a distribution deal in March 2008?

Companies Mentioned:

-3DM

-AAP Implantate

-Aastrom Biosciences

-Abbott Spine

-Allograft Tissue Systems Inc (ATSI)

-Allosource

-Alphatec Spine

-Apatech

-Arthro Kinetics

-Berkeley Advanced Biomaterials

-Biomet

-Biomimetic Therapeutics

-Bioniche Pharma

-Biosyntech

-co.don AG

-Collagen Matrix

-CSIRO

-Curasan AG

-DePuy

-ETEX Corporation

-Exactech

-Ferring Pharmaceuticals

-Fidia Advanced Biopolymers

-Geistlich Biomaterials

-Genzyme

-Graftys

-Integra Lifesciences

-ISTO Technologies

-Kasios

-Kinamed

-Lifecell

-Lifenet Health

-Magnecell

-Mica

-Medtronic

-Mesoblast

-Nanocoatings Pty Ltd

-Nanotherapeutics

-Orthofix

-Orthomimetics

-Orthovita

-Osiris

-Ossacur

-Osteotech

-Pegasus Biologics

-Regen Biologics

-RTI Biologics

-Smith & Nephew

-Spinal Restoration

-Stellar Pharmaceuticals

-Stryker

-Synthes

-Tigenix

-TRB Chemedica

-Wright Medical

-Zimmer

For more information, visit http://www.researchandmarkets.com/reports/c92536

Source: Business Wire

More News in this Category